October 2023 NCICT Newsletter

Dear all,

October seemed to fly by! This month, we hosted the NCIC Symposium and Workshop – “Pathways to better infection care in cancer”.

I would like to take an opportunity to thank our guest speakers, Prof Melissa Baysari from University of Sydney, Dr Ashley Ng from Department of Health Services Research PMCC, and Dr Lisa Guccione from Department of Health Services of Research and Implementation Science PMCC, for sharing their valuable insights. And many thanks to the NCIC team for collaborating so seamless over the past few weeks to make this workshop a success!


Dr Dan Yeoh PhD Completion Seminar

On another positive note, I would like to congratulate Dr Dan Yeoh on completing his PhD in Invasive fungal Disease in children with cancer: Improving diagnosis, optimising antifungal prescribing, and exploring prospective surveillance.

Farewell Dr Galadriel Pellejero from Spain

Last week marked the end of Dr Galadriel Pellejero visiting fellowship with NCIC. During her fellowship, Galadriel attended clinical ward rounds at PMCC and RMH as well as outpatients and ICU. She gave a talk about AMS practices including development of an app to the NCAS group and was involved with project work and a project proposal with definitions around BK viremia and disease in the allo-HSCT population. We hope to continue the collaboration including catch-up in Barcelona at ECCMID 2024.


Other upcoming events

ANZMIG Mycology Masterclass 2023

2nd - 4th November 2023

‘Preventing and treating fungal infections, one course at a time’

NCIC Presenters:
Prof Monica Slavin ‘‘Treatment trials, and unmet needs’ and chairing the session Non-Aspergillus Mould Infections”
Dr Abby Douglas “Antifungal Stewardship
A/Prof Ben Teh “Prevention of Aspergillosis”
Dr Michelle Yong “Fungal-respiratory Virus Co-infections”


Antibiotics Awareness Week 2023 (AAWS)

led by Prof Karin Thursky

Thursday 23rd November 2023
4pm to 7pm
Level 7, Peter MacCallum Cancer Centre

NCIC Presenters:
A/Prof Gabrielle Haeusler, Prof Jason Trubiano, Dr Olivia Smibert


National Antimicrobial Prescribing Survey (NAPS)

led by Prof Karin Thursky

A hybrid event celebrating the many successes of the National Antimicrobial Prescribing Survey (NAPS) as the program turns TEN in 2023.

Friday 24th November 2023
2pm to 5pm
Charles LaTrobe Theatre, Royal Melbourne Hospital


Learning Health System (LHS) Academy Symposium

Come along to the LHS Academy Symposium to hear of the latest LHS projects led by our 2023 Academy Fellows.

Our very own Belinda Lambros will be presenting in a panel discussion.

Wednesday 29th November 2023
3:30pm to 7:00pm
Forum 1 & 2, Melbourne Connect, 700 Swanson Street (hybrid event)


PhD Spotlight

Dr Victoria Hall

Infectious Diseases Physician,
PhD Candidate, NCIC

Victoria is an Infectious Diseases physician and second year PhD student at the NCIC, Peter MacCallum Cancer Centre (PMCC). She completed her Infectious Diseases training in Melbourne at the Austin and Alfred Hospitals in 2020.

To further her clinical and research experience, she undertook a Transplant and Oncology Infectious Diseases Fellowship at the University Health Network, through University of Toronto, Toronto, Canada, from mid 2020 – end of 2021. During the COVID-19 pandemic, supervised by leaders in the field including Professors Deepali Kumar and Atul Humar, she led work studying COVID-19 infection and vaccine immune response in solid organ transplant recipients. This included a practice changing randomised control trial of a third dose of COVID-19 vaccine, leading to FDA and then international approval for all immunocompromised patients.

This has inspired her current NHMRC-supported translational PhD, examining burden and host immune response of respiratory virus infection in patients with haematological malignancy, supervised by Professor Monica Slavin, A/Prof Benjamin Teh, Dr Michelle Yong and Professor Katherine Kedzierska. As part of her PhD, she has been successful in securing research support funding as a co-investigator from a PMCC Foundation grant, professional development support from the Rosie Lew PMCC Foundation Postgraduate award and as principal investigator from the Government of Victoria, Victorian COVID-19 Vaccinees Collection (VC2) COVID-19 Research seed funding. In addition, she was recognised by the Transplant Infectious Diseases (TID) journal as an inaugural recipient of the Dr Francisco Marty TID Journal Editorial Fellowship for 2023.  She has presented her work in oral abstract form at ECCMID 2023, American Transplant Congress 2022 and successfully published seven first author publications in internationally recognised, peer reviewed Infectious Diseases and Haematology journals.

She looks forward to her upcoming third year of PhD, with further research work expected including assessment of influenza vaccination strategies and current epidemiology of respiratory viruses in patients with haematological malignancy.


Feature Paper

Invasive Aspergillosis in adult patients in Australia and New Zealand: 2017–2020

Tio SY, Chen SC, Hamilton K, Heath CH, Pradhan A, Morris AJ, Korman TM, Morrissey O, Halliday CL, Kidd S, Spelman T, Brell N, McMullan B, Clark JE, Mitsakos K, Hardiman RP, Williams P, Campbell AJ, Beardsley J, Van Hal S, Yong MK, Worth LJ, Slavin MA.

“This is one of the largest, multicenter in-depth clinical-epidemiologic evaluation of adult invasive aspergillosis (IA) cases in the Southern Hemisphere, with 221 proven and probable IA cases from ten healthcare institutions in Australia and New Zealand. Salient findings as follows: a) 12% of patints who developed IA were with mild or no immunosuppression; b) neutropenia was less common in this cohort and itself was not associated with mortality; c) with 6.5% azole-resistance rate amongst 46 tested A. fumigatus isolates. Therefore it is important to be aware of IA in patients without traditional host factors, and to perform accurate identification of Aspergillus species with susceptibility testing to guide management.” - Dr Shio Yen Tio

“Congratulations Shio Yen on completing this large multi-centre study! With data from 10 hospitals to co-ordinate and clean it was a big task but an important part of your PhD.   Thanks also go to Prof Sharon Chen, Kate Hamilton for helping oversee the study and ANZMIG for support.” - Prof Monica Slavin


Recent publications

High Rates of Seroprotection and Seroconversion to Vaccine-Preventable Infections in the Early Post-Autologous Stem Cell Transplant Period. Hall et al

CMV prevention strategies in allogeneic hematopoietic cell transplantation; the role of prophylaxis and pre-emptive monitoring in the era of letermovir. Yong et al

A protocol for an international, multicentre pharmacokinetic study for Screening Antifungal Exposure in Intensive Care Units: The SAFE-ICU study. Roberts et al


Kind regards

Prof Monica Slavin, MBBS, MD, FRACP, FAAHMS
Head, Department Infectious Disease, Peter MacCallum Cancer Centre

Professor of Infection in Cancer and Transplantation, University of Melbourne Department of Infectious Diseases and the Sir Peter MacCallum Department of Oncology

Director, National Centre for Infections in Cancer and Transplantation

September 2023 NCICT Newsletter

Dear all,

September was a busy month for NCIC with plenty of meetings and activities. A big thank you and shout out to the whole NCIC team who had successfully hosted the Taiwanese visitors, Dr Ting-Yu Yen (paediatric ID physician) and Shih-Han Chen (Research Nurse) from National University of Taiwan.

Fellow of IDSA

I am delighted to share that I have been named a Fellow by the Infectious Diseases Society of America (IDSA). The IDSA is an organisation of over 12,000 physicians, scientists, public health experts and other health care professionals dedicated to promoting health through excellence in infectious diseases research, education, prevention and patient care. I look forward to working and learning alongside them. For more information, visit www.idsociety.org.

NCIC Symposium and Workshop

Next month we will focus on the NCIC Symposium and Workshop. If you can, please join us for a full day symposium providing a comprehensive update on new pathways of care and novel interventions to deliver best practice care for treating and preventing infection in cancer. This symposium will be practical and interactive, with the opportunity to speak with experts in infectious diseases, health services research and implementation to help tailor interventions to your setting. More details and registration link available below.


“I wanted to extend my heartfelt thanks for the two-week training program you provided. It was an absolute honour to have the opportunity to visit Australia, explore Melbourne, train at Peter MacCallum, RMH, and meet the NCIC team.”

- Shih-Han Chen, Research Nurse National University of Taiwan


NCIC Symposium and Workshop

In person, Friday 6th October 2023
10am-4pm, Graduate House, UoM

Pathways to better infection care in cancer

Venue: Graduate house, University of Melbourne, Melbourne, Australia.  220 Leicester Street Carlton VIC 3053

Target audience: Medical, nursing, pharmacy practitioners involved in cancer care, including regional centres.

Ticket price: $150 for medical practitioners, $50 for nurses/pharmacist/allied health


Other upcoming events

VIDS Seminar

Monday 2nd October
12:30pm - 1:30pm AEST

“Update on CMV in the immunocompromised host”
Presented by Dr Michelle Yong

ANZMIG Mycology
Masterclass 2023

2nd to 4th November

NCIC Presenters:
Dr Abby Douglas, A/Prof Ben Teh and Dr Michelle Yong


Feature Paper

Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients.

Teh BW, Mikulska M, Averbuch D, de la Camara R, Hirsch HH, Akova M, Ostrosky-Zeichner L, Baddley JW, Tan BH, Mularoni A, Subramanian AK, La Hoz RM, Marinelli T, Boan P, Aguado JM, Grossi PA, Maertens J, Mueller NJ, Slavin MA.

The Lancet Infectious Diseases

“This is a consensus statement regarding the need to adequately capture information about infection in clinical trials and registries related to immunocompromised patients including cancer and transplant patients.  A/Prof Ben Teh led this work along with me and two colleagues from Europe: Prof Mikulska (Italy) and Prof Mueller (Switzerland) and it was endorsed and contributed to by 7 international societies including US and European groups focused on care of immunocompromised patients as well as our Australasian Society for Infectious Diseases.” - Prof Monica Slavin

“While there is still a lot to do to improve our reporting of infections, this work is an important start providing a tool to enable researchers to pool research data and ensure interstudy comparability. This will move research in this field forwards.” - A/Prof Ben Teh


Recent publications

Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients. Teh et al

Goals to score: The need for a minimum reporting dataset in studies of infection events in immunocompromised patients. Teh et al

Invasive aspergillosis in adult patients in Australia and New Zealand: 2017-2020. Tio et al

Recommendations on prevention of infections in patients with T-cell lymphomas: a narrative review and synthesis. Reynolds et al


Kind regards

Prof Monica Slavin, MBBS, MD, FRACP, FAAHMS
Head, Department Infectious Disease, Peter MacCallum Cancer Centre

Professor of Infection in Cancer and Transplantation, University of Melbourne Department of Infectious Diseases and the Sir Peter MacCallum Department of Oncology

Director, National Centre for Infections in Cancer and Transplantation

August 2023 NCICT Newsletter


View the August NCIC Seminar

Prof Karin Thursky and Mr Nikhil Singh

Exploring the Pros and Cons of Fluoroquinolone Prophylaxis in Neutropenic Fever HERE.


World Sepsis Day,

Sept 13th

We are also hosting World Sepsis Day activities on Sept 13th, with plenty of cupcakes and give away’s. Keep your eyes out for our AMS NP Belinda Lambros if you are in the precinct.


ANZMIG Mycology Masterclass 2023

2nd - 4th November

NCIC Presenters: A/Prof Ben Teh and Dr Michelle Yong

Dear all,

September is looking like another busy month for NCIC with plenty of upcoming meetings and activities. Next week I will be giving the NCIC Seminar for September on New Antifungals. Sept 7th at 12.30pm. You can register for the zoom link below. 

International Visitors

September is also a busy month for visitors to our centre. We will be hosting Drs Galadriel Pellejero from Spain,  Dr Daphne Lau from Hong Kong and Dr Yan and Shih Han Chen from Taiwan. Drs Pellejero and Lau will be joining us for several months to observe our clinical practice and AMS activities in particular. While Dr Yan and Shih Han will be joining us for 2 weeks to learn how we run our clinical trial group. Welcome to all our International visitors!

Eureka Prize

Congratulations also to our colleagues at the Doherty Professor Katherine Kedzierska, PhD FAHMS and Dr Oanh Nguyen on your much deserved Eureka prize! It is wonderful collaborating with your group and the insights into vaccine responses in cancer are so valuable to our patients. Enjoy this wonderful recognition of your contribution to science.


NCIC Symposium and Workshop

In person, Friday 6th October 2023, 10am-4pm, Graduate House, UoM

Pathways to better infection care in cancer

A full day symposium providing a comprehensive update on new pathways of care and novel interventions to deliver best practice care for treating and preventing infection in cancer. This symposium will be practical and interactive, with the opportunity to speak with experts in infectious diseases, health services research and implementation to help tailor interventions to your setting.

Venue: Graduate house, University of Melbourne, Melbourne, Australia.  220 Leicester Street Carlton VIC 3053

Target audience: Medical, nursing, pharmacy practitioners involved in cancer care, including regional centres.

Ticket price: $150 for medical practitioners, $50 for nurses/pharmacist/allied health


Feature Paper

Risky business: The impact of antimicrobial prescribing on multidrug-resistant Gram-negative BSIs in acute myeloid leukemia patients.

Transplant Infectious Disease

Beatrice Z Sim, Monica A Slavin, Abby P Douglas

The editorial written by our fellow Dr Beatrice Sim under the guidance of Dr Abby Douglas and Prof Monica Slavin discusses a paper in TID correlating duration of antibiotics and emergence of resistant gram negative infection in AML patients. The theme of shorter duration of antibiotics is also discussed in the paper by Imlay, Laundy et al and is one we are focussing on with upcoming studies in collaboration with our haematology colleagues. A/Prof Gab Haeusler is already conducting an electronic medical record-embedded randomised clinical trial comparing shorter course antibiotics to standard course in children with fever and neutropenia at RCH and MCRI and we are currently in the process of designing a similar study in adult patients. This topic is very relevant to our patients and we aim to soon add to the evidence around stopping antibiotics early in stable patients with fever and neutropenia.


Recent publications

Shorter antibiotic courses in the immunocompromised: the impossible dream? Imlay et al

The antifungal pipeline for invasive fungal diseases: what does the future hold? Neoh et al

Parvovirus B19 in stem cell transplantation. Kinsella et al

Invasive fungal infections after CLAG-M/CLAG chemotherapy for acute myeloid leukemia and high-grade myeloid neoplasms. Lindsay et al

Invasive aspergillosis in liver transplant recipients. Melenotte et al

Multidrug-resistant Enterobacterales infections in abdominal solid organ transplantation. Pilmis et al

Risky business: The impact of antimicrobial prescribing on multidrug-resistant Gram-negative BSIs in acute myeloid leukemia patients. Sim et al

Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial. Thompson et al


Kind regards

Prof Monica Slavin, MBBS, MD, FRACP, FAAHMS
Head, Department Infectious Disease, Peter MacCallum Cancer Centre

Professor of Infection in Cancer and Transplantation, University of Melbourne Department of Infectious Diseases and the Sir Peter MacCallum Department of Oncology

Director, National Centre for Infections in Cancer and Transplantation

July 2023 NCICT Newsletter

Dear all,

We are very proud to announce two new grants, one to Prof Leon Worth, “Appling artificial intelligence for surveillance of infections in cancer”, and one to Prof Karin Thursky “Optimising real world data use to drive cancer care delivery and research”. Both were awarded through the MRFF National Critical Research Infrastructure Initiative, to a total value of over $5.5 million over the next 5 years. Congratulations to both, we are looking forward to working closely with NCIC collaborators at RMIT (School of Computer Science), Biogrid, Melbourne Health and UoM (Centre for digital transformation of Health) on these initiatives.  These initiatives will be crucial to driving research froward in the current era of data science, big data and artificial intelligence.

Our very own AMS NP Belinda Lambros represented NCICT in Adelaide at the Cancer Nurses Society of Australia (CNSA) annual meeting, giving a workshop in Advanced Practice of ID. Great work Bel!

Congratulations also to NCIC PhD Dr Beatrice Sim on her appointment to the ASID council as a new representative.

Seminars and Journal Club

NCICT Journal Club

Monthly, Fridays 12 pm

The next NCICT Journal Club series is this Friday July 28th 12-1 pm with NCICT NP Belinda Lambros and nurse PhD candidate Alison Lemoh presenting. Sign up for a live link to the NCIC Journal Club series HERE.

Papers:

Quality of life and mortality in older adults with sepsis after one-year follow up: A prospective cohort study demonstrating the significant impact of frailty. Dong et al

A call for better doctor nurse collaboration: A qualitative study of the experiences of junior doctors and nurses in escalating care for deteriorating ward patients. Legido-Quigley et al

Factors influencing the activation of the rapid response system for clinically deteriorating patients by frontline ward clinicians: a systematic review. Chua et al

 

NCICT Seminar series

Upcoming

Thursday August 3rd, 12.30-1.30

Exploring the Pros and Cons of Fluoroquinolone Prophylaxis in Neutropenic Fever

Prof Karin Thrursky and Nikhil Singh

Register for link HERE

Previous

Dr Michelle Yong: New developments in managing CMV in transplant recipients

View HERE


Feature Paper

COVID-19 infection among patients with cancer in Australia from 2020 to 2022: a national multicentre cohort study

The Lancet Regional Health - Western Pacific

Victoria G. Hall, Beatrice Z. Sim, Chhay Lim, Christopher Hocking, Teddy Teo, Naomi Runnegar, Peter Boan, Christopher H. Heath, Natalie Rainey, Megan Lyle, Christopher Steer, Eunice Liu, Cassandra Doig, Kate Drummond, Patrick G.P. Charles, Katharine See, Lyn-Li Lim, Omar Shum, Narin Bak, Sue-Anne MclachlanBenjamin W. Teh.

The largest study to date into the pandemic’s impact on Australian cancer patients - a uniquely vulnerable group - has found the rate of deaths did not meet international projections and attributes the wide uptake of COVID vaccinations, less severe omicron variant and early intervention antiviral treatments, as saving lives. 

The study led by NCICT PhD candidate Dr Victoria Hall and Dr Ben Teh assessed 620 cancer patients across 15 Australian hospitals who caught COVID-19 from March 2020 to April 2022. 

 All-cause mortality in these patients in the 100 days after their COVID-19 infection was 10.6% overall – well below the mortality figures seen internationally of 30% to 38% for patients with blood cancers, considered one of the highest risk groups.

 “We found overall that one in ten Australian cancer patients who caught COVID-19 died within 100 days of the infection, either as a result of COVID-19 or an unrelated cause, and while this is a significant loss of human life it is well short of what was seen elsewhere for this vulnerable patient group,”  

“Contributing factors include that most Australian cancer patients caught COVID-19 in early 2022 during the Omicron wave and after COVID vaccines had become widely available, and there were also measures in place to rapidly detect infections and provide early protective antiviral treatments to this group.”

Dr Hall said that this study found that the Omicron variant also appears to be less severe than previous strains in patients with cancer, similar to what has been suggested in the general population. The average age of Australian cancer patients who caught COVID-19 was 63.5 years, with slightly more men (50.6%) and overall, 73.4% were vaccinated against COVID-19.

The rate of deaths declined over the course of the pandemic, with all-cause mortality in 2020 at 25.6% but in 2022 it was 8.1% in patients with cancer and COVID-19.

 “Just as we saw deaths in this vulnerable group decline over time there were also consistent drops in the rate of patients needing a hospital stay of more than 24 hours, those who required oxygen or an ICU stay, and those who required mechanical ventilation,” Dr Hall said. 


Kind regards

Prof Monica Slavin, MBBS, MD, FRACP, FAAHMS
Head, Department Infectious Disease, Peter MacCallum Cancer Centre

Professor of Infection in Cancer and Transplantation, University of Melbourne Department of Infectious Diseases and the Sir Peter MacCallum Department of Oncology

Director, National Centre for Infections in Cancer and Transplantation

May 2023 NCICT Newsletter

Dear all,

 April was an incredibly busy month for conference attendance.

 ECCMID

I was honoured to give the opening plenary lecture (entitled Frontiers in the diagnosis and management of infections in the immunocompromised host) at the European Conference on Clinical Microbiology and Infectious Diseases (ECCMID); the largest international Infectious Diseases meeting attended by 15,000 delegates, May 2023, Coppenhagen. 

Also present to represent Peter Mac and the Infectious diseases research being conducted by the National Centre for Infections in Cancer and Transplantation (NCICT) were Prof Karin Thursky, A/Prof Gabrielle Haeusler, Drs Michelle Yong, Victoria Hall, Daniel Yeoh, Gemma Reynolds and Ms Kar Yee Yong. All listed presented research and Dr Ben Teh also attended to support presentations by PhD students.

ASID

We had 3 PhD candidates presenting as well as one masters of public health student represent at ASID. Highlights include being awarded a lifetime member and having my name on the Adelaide oval scoreboard

Otherhighlights were Dr Shio Yen Tio winning the 2023 ANZMIG Mycology SIG award and meeting Professor Glaukenflucken.

@NCICancer twitter has now reached influencer status with over 1000 followers

 

May also saw NCICT Drs, Michelle Yong, Liv Smibert, Beatrice Sim, Megan Crane and Shio Yen Tio attend the Fred Hutch Symposium on Infections in the immunocompromised Host in Seattle and Rachel Woolstencroft, Drs Ben Teh, Zoe Neoh and Karin Thursky present at the Peter Mac Research Symposium. Jason Trubiano held a highly successful drug allergy symposium at the Doherty shortly after his appointment to full Professor. Congratulations Prof Trubiano!

Seminars and Journal Club

NCICT Journal Club

Monthly, Fridays 12 pm

The third of the 2023 monthly NCICT Journal Club series is this Friday June 2nd 12-1 pm with Dr. Morgan Rose presenting. Sign up for a live link to the NCIC Journal Club series HERE.

 

NCICT Seminar series

Thursday June 8th, 12.30-1.30

Dr Michelle Yong: New developments in managing CMV in transplant recipients

Register for link


Feature Paper

Current epidemiology and clinical features of Cryptococcus infection in patients without HIV infection: a multicentre study in 46 hospitals from Australia and New Zealand.

Clin Infect Dis. 2023 May 26:ciad321. doi: 10.1093/cid/ciad321. Epub ahead of print. PMID: 37235212.

Coussement J, Heath CH, Roberts MB, Lane RJ, Spelman T, Smibert OC, Longhitano A, Morrissey O, Nield B, Tripathy M, Davis JS, Kennedy KJ, Lynar SA, Crawford LC, Crawford SJ, Smith BJ, Gador-Whyte AP, Haywood R, Mahony AA, Howard JC, Walls GB, O'Kane GM, Broom MT, Keighley CL, Bupha-Intr O, Cooley L, O'Hern JA, Jackson JD, Morris AJ, Bartolo C, Tramontana AR, Grimwade KC, Au Yeung V, Chean R, Woolnough E, Teh BW, Chen SC, Slavin MA; Australian and New Zealand study group for cryptococcosis in patients without HIV infection.

During his 2 years at NCIC in Melbourne, visiting ID physician Dr Julien Coussement completed this study of cryptococcosis in patients without HIV infection showing that in Australia and New Zealand this is by far the most common population in which cryptococcosis is seen. Whilst around 60% of this population have a recognised form of immunocompromise, the rest do not. Signs and symptoms may be subtle, or not present at all, as evidenced by the 16% of cases where cryptococcosis was an incidental finding on imaging performed for another reason. Interestingly, in this population CNS involvement was often predicted by a high serum cryptococcal antigen or fungemia. This work helps our understanding of the infection outside of the population of people living with HIV. Congratulations Julian for co-ordinating the 46 sites in Australia and New Zealand-no mean feat! Many thanks to all our collaborators who are acknowledged as authors or as members of the Australian and New Zealand study group for cryptococcosis in patients without HIV infection in the journal and on-line.


Kind regards

Prof Monica Slavin, MBBS, MD, FRACP, FAAHMS
Head, Department Infectious Disease, Peter MacCallum Cancer Centre

Professor of Infection in Cancer and Transplantation, University of Melbourne Department of Infectious Diseases and the Sir Peter MacCallum Department of Oncology

Director, National Centre for Infections in Cancer and Transplantation

March 2023 NCICT Newsletter

Dear all,

For this month’s newsletter I am pleased to feature our newly promoted General Manager, Infectious Diseases, Peter MacCallum Cancer Centre- Dr Megan Crane PhD, MIDI. Megan began with us in 2017 as the Research Manager for the newly awarded NCIC Centre for Research Excellence with 10 years’ experience as a laboratory Post Doc in Immunology. Over her last 6 years as Research Manager, she has been instrumental in developing and implementing the strategic, operational and business plans of the department, growing the department from 10 people with an annual operating budget of $500,000 to a multidisciplinary clinical research team of 36 with an annual budget of $2 million. During this time Megan also completed a Masters of Infectious Disease Intelligence (UNSW).   I am extremely pleased to have supported Megan in her promotion to General Manager of ID at Peter Mac, a well deserved reflection of her hard work and commitment to world’s best cancer care.  

 

Congratulations Megan, we look forward to continued growth and development of the National Centre for Infections in Cancer and Transplantation.

Congratulations also to Drs Shio Yen Tio and Beatrice Sim on being successful recipients of an  Abstract and Travel Stipend Award - 4th Symposium on Infectious Diseases in the Immunocompromised Host, to present their work at Fred Hutch, Seattle in May this year. Drs Sim and Tio and other NCICT researchers will be attending to share experience and build collaborations with the international transplant infectious diseases community. We are also looking forward to seeing many of our ID colleagues at ASID 2023 this weekend and will have 3 abstracts presented by our research team.

We also have 7 abstracts to be presented at ECCMID and I will be giving a keynote lecture on Frontiers in Infection in the ICH.  Well done to the team for having abstracts accepted at these 3 important meetings.


Seminars and Journal Club

NCICT Journal Club

Monthly, Fridays 12 pm

The second of the 2023 monthly NCICT Journal Club series is this Friday March 31st 12-1pm with Dr. Gemma Reynolds (paper) and Dr. Pedro Puerta (Fungal Infection in ICH) .Sign up for a live link to the NCIC Journal Club series HERE.

 

You can now view the recording of Prof Graeme Forrest who gave a fantastic presentation at the NCICT Seminar Series on AMS in TID HERE

 

The Straight and Marrow Podcast

Podcast | Straight and Marrow

Dr Michelle Yong (guest episode 13), an infectious diseases expert, answers all of our questions about infectious diseases in bone marrow transplant patients. We discuss neutrophils, cytomegalovirus, preventative measures and discuss what is the real “F” word in transplantation.


Publication highlight

Robust SARS-CoV-2 T cell responses with common TCRαβ motifs towards COVID-19 vaccines in haematological malignancy patients impacting B cell immunity

Thi H O Nguyen, Louise C Rowntree, Lilith F Allen, Brendon Y Chua, Lukasz Kedzierski, Chhay Lim, Masa Lasica, G Surekha Tennakoon, Natalie R Saunders, Megan Crane, Lynette Chee, John F Seymour, Mary Ann Anderson, Ashley Whitechurch, E Bridie Clemens, Wuji Zhang, So Young Chang, Jennifer R Habel, Xiaoxiao Jia, Hayley A McQuilten, Anastasia A Minervina, Mikhail V Pogorelyy, Priyanka Chaurasia, Jan Petersen, Tejas Menon, Luca Hensen, Jessica Neil, Francesca L Mordant, Hyon-Xhi Tan, Aira F Cabug, Adam K Wheatley, Stephen J Kent, Kanta Subbarao, Theo Karapanagiotidis, Han Huang, Lynn K Vo, Natalie L Cain, Suellen Nicholson, Florian Krammer, Grace Gibney, Fiona James, Janine M Trevillyan, Jason A Trubiano, Jeni Mitchell, Britt Christensen, Katherine A Bond, Deborah A Williamson, Jamie Rossjohn, Jeremy Chase Crawford, Paul G Thomas, Karin A Thursky, Monica A Slavin, Constantine S Tam, Benjamin W Teh, Katherine Kedzierska

Published in Cell Reports Medicine (preprints), led by University of Melbourne Professor Katherine Kedzierska (Doherty Institute), in collaboration with Associate Professor Benjamin Teh, Professor Monica Slavin, Surekha Tennakoon, Natalie Suanders, Dr Megan Crane  and Professor Jason Trubiano (NCICT).

Despite being heavily immunocompromised, haematology patients generate strong cellular immune responses against SARS-CoV-2 after vaccination, on par with that of healthy individuals. The research team undertook the most comprehensive analysis of adaptive SARS-CoV-2 immunity to date in haematology patients of varying diseases and treatments across three doses of COVID-19 vaccination in comparison to healthy individuals.

Professor Kedzierska says that the study provides key insights for future immunisation strategies with vaccines such as influenza which predominantly induce B cell immune responses.

“What we have shown is that people with co-morbidities that have a heavily impacted B cell immune arm, can have an mRNA vaccine to elicit T cells and give them that extra level of protection,” Professor Kedzierska says

Associate Professor Teh says this research is important for clinicians working with blood cancer patients.

“Clinicians can be confident that it is safe and beneficial for their patients, who are heavily immunocompromised and vulnerable to severe COVID-19 infection, to receive vaccination against SARS-CoV-2. Regardless of their diseases and treatments, COVID-19 vaccination generates strong T cell immunity in this group,” Associate Professor Teh says.


Recent Publications

Survey of treatment practices for immunocompromised patients with COVID-19 in Australasia.

Moso MA, Sasadeusz J, Morrissey CO, Bond K, Guy S, Slavin MA, Dendle C.Intern Med J. 2023 Mar 17. doi: 10.1111/imj.16064. Online ahead of print.PMID: 36929677

 Invasive aspergillosis in liver transplant recipients.

Melenotte C, Aimanianda V, Slavin M, Aguado JM, Armstrong-James D, Chen YC, Husain S, Van Delden C, Saliba F, Lefort A, Botterel F, Lortholary O.Transpl Infect Dis. 2023 Mar 16:e14049. doi: 10.1111/tid.14049. Online ahead of print.PMID: 36929539 Review.

 Infectious complications of bispecific antibody therapy in patients with multiple myeloma.

Sim BZ, Longhitano A, Er J, Harrison SJ, Slavin MA, Teh BW.Blood Cancer J. 2023 Mar 10;13(1):34. doi: 10.1038/s41408-023-00808-8.PMID: 36894539 Free PMC article. No abstract available

View all NCICT publications HERE


Kind regards

Prof Monica Slavin, MBBS, MD, FRACP, FAAHMS
Head, Department Infectious Disease, Peter MacCallum Cancer Centre

Professor of Infection in Cancer and Transplantation, University of Melbourne Department of Infectious Diseases and the Sir Peter MacCallum Department of Oncology

Director, National Centre for Infections in Cancer and Transplantation